Interchangeable Biosimilar Designations Shouldn't Be Forever, Innovators Say
Executive Summary
US FDA may need to withdraw previous interchangeability determination due to new indications or manufacturing changes, reference product companies say; generic firms say prior interchangeability designation should apply to new indications absent significant scientific questions.
You may also be interested in...
Best Of Biosimilar Agreement: FDA, Industry Tout Written Response, Pre-Submission Meeting
FDA's Leah Christl and Amgen and Sandoz representatives discuss key achievements of BsUFA II at DIA meeting; Christl expects to see interchangeable biosimilars come to market within the next two years.
Best Of Biosimilar Agreement: FDA, Industry Tout Written Response, Pre-Submission Meeting
FDA's Leah Christl and Amgen and Sandoz representatives discuss key achievements of BsUFA II at DIA meeting; Christl expects to see interchangeable biosimilars come to market within the next two years.
Next Steps For Interchangeable Biosimilars: Lifecycle Regulation Policy Development
US FDA seeks stakeholder views on manufacturing changes, new reference product indications and other questions that build on its draft guidance for approval of interchangeable biosimilars.